PRIDE is short for “PReoperative Image-guided IDentification of response to neoadjuvant
chemoradiotherapy in Esophageal cancer”.
The PRIDE trial is a multicenter observational study and is a collaboration between the Netherlands Cancer Institute (NKI), the University Medical Center Groningen (UMCG), the
Academic Medical Center Amsterdam (AMC) and the University Medical Center Utrecht (UMCU). This project is supported by funds of Alpe d’Huzes, partner of the Dutch Cancer Society.
Our aim is to develop a multiparametric prediction model with PET-CT and MRI scans that predicts the response to neoadjuvant chemoradiotherapy in esophageal cancer. Our goal is to include 200 patients amongst the participating centers.